Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

nCino Unveils Latest Enhancements to its Consumer Banking Solution 1-04-2024, 19:45

18th Business Symposium at the Yacht Club de Monaco 2-02-2026, 23:31